间变性淋巴瘤激酶
肺癌
医学
靶向治疗
酪氨酸激酶
临床试验
埃罗替尼
表皮生长因子受体
酪氨酸激酶抑制剂
肿瘤科
克里唑蒂尼
癌症研究
癌症
内科学
受体
恶性胸腔积液
作者
Bo Mi Ku,Jong‐Mu Sun,Se-Hoon Lee,Jin Seok Ahn,Keunchil Park,Myung‐Ju Ahn
标识
DOI:10.1080/14737159.2017.1372196
摘要
Introduction: The discovery of activating genetic and their use as predictive biomarkers for targeted therapy, such as tyrosine kinase inhibitors (TKIs), has changed the treatment paradigm of non-small cell lung cancer (NSCLC). As a result, epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) TKIs have become the standard first-line treatment. Since then, other kinds of targetable oncogenic alterations have been identified in NSCLC. Several novel, molecularly-targeted TKIs have now achieved regulatory approval, while many others are currently in early- or late-phase clinical trial testing. These TKIs have significantly impacted and changed clinical outcomes for advanced NSCLC.Areas covered: In this review, the authors discuss recent evidence and progress in targeted therapies, especially small molecular tyrosine kinase inhibitors, matched with their biomarkers for the treatment of advanced NSCLC.Expert commentary: Although targeted therapies dramatically improve the outcome of patients with NSCLC harboring specific oncogenic alterations, molecular and clinical resistance almost invariably develops. New TKIs specifically active in molecular subgroups of NSCLC or the resistance setting have now been developed. The development of additional TKIs and rational combinations may further improve outcomes of NSCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI